FDA approves Saxenda for adolescents 12 and older, the first GLP-1 drug for pediatric weight management

On December 4, 2020, the FDA approved Saxenda (liraglutide 3.0 mg) for weight management in patients aged 12 and older with obesity. It is the first GLP-1 receptor agonist cleared in the United States for pediatric weight management. The decision rested on SCALE TEENS, a 56-week randomized trial that enrolled 251 adolescents.

What the available record shows

The source documents available for this report do not include the FDA approval letter, the Saxenda prescribing information, or the published SCALE TEENS results. That means the trial's specific weight and BMI changes, side-effect rates, dropout numbers, and the exact label criteria (such as required body weight or BMI cutoffs for teens) are not verifiable here and should not be inferred. Those details are not yet established in this record.

What the available sources do document is the size of the problem the approval addresses. About 14.1 million children and adolescents in the United States are affected by obesity ^[2]. In the 2015–2016 NHANES survey, obesity affected 18.5% of Americans aged 2 to 19, including 20.6% of those aged 12 to 19 — the highest rate of any age band measured ^[2]. Severe obesity was also common: class 2 obesity affected 5.2% of girls and 6.7% of boys, and class 3 obesity affected 1.8% of girls and 2.0% of boys in 2015–2016 ^[2]. Childhood obesity prevalence rose between 2011 and 2020 ^[2].

Pediatric weight categories are defined by BMI percentile rather than a single number. Overweight is a BMI at or above the 85th percentile and below the 95th percentile, obesity is at or above the 95th percentile, and severe obesity is at or above 120% of the 95th percentile for age and sex ^[1][2].

Why it matters for patients

Before this approval, families of adolescents with obesity had few FDA-cleared medication options, and prescribing a GLP-1 drug to a 12- or 15-year-old meant using an adult product outside its labeled age range. An age 12-and-older indication changes that: it gives clinicians a reviewed, labeled pathway, and it typically strengthens the case families make to insurers. Whether individual plans, Medicaid programs, or employers cover Saxenda for teens is not addressed in these sources.

The approval also lands in a clinical context where obesity is treated as a chronic condition, not a short-term problem. The American Academy of Pediatrics' clinical practice guideline describes obesity as a complex chronic disease and states that children with overweight or obesity should be offered treatment upon diagnosis ^[1][2]. The guideline's key action statements call for pediatricians to measure height, weight, and BMI percentile at least annually for all children 2 to 18 ^[1][2]; to evaluate children with overweight or obesity for related conditions using history, mental and behavioral health screening, social-determinants review, physical exam, and lab studies ^[2]; and to treat obesity and its comorbidities at the same time rather than in sequence ^[2]. Those comorbidities include type 2 diabetes, high blood pressure, sleep apnea, nonalcoholic fatty liver disease, and depression ^[2].

One practical limit worth noting: SCALE TEENS ran 56 weeks. Longer-term data in adolescents — on growth, puberty, bone health, mental health, or what happens after stopping — are not part of the material reviewed here.

What happens next

The AAP published its comprehensive clinical practice guideline for evaluating and treating children and adolescents with obesity in the February 2023 issue of Pediatrics, the first such comprehensive guidance in 15 years ^[1][2]. That document was built from a review that screened about 16,000 abstracts, examined 1,642 full-text articles, and included 382 studies, with searches running through February 15, 2020 ^[2]. It produced 13 key action statements and 11 consensus recommendations ^[2].

Whether other GLP-1 medicines follow liraglutide into pediatric use, and on what timeline, is not covered by these sources. Decisions about any weight-management medication for a teenager involve a clinician who knows the patient's history.